Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DL

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DL
AbbVie (NYSE: ABBV) Delayed: 230.01 +13.52 (6.25%)
Previous Close $216.49    52 Week High $68.12 
Open $221.94    52 Week Low $50.71 
Day High $232.32    P/E 49.89 
Day Low $221.94    EPS $4.61 
Volume 9,912,419       

(NASDAQ: GMAB) Delayed: 25.61 +0.34 (1.35%)
Previous Close $25.27    52 Week High $ 
Open $25.05    52 Week Low $ 
Day High $25.66    P/E N/A 
Day Low $25.16    EPS $ 
Volume 1,593,105